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Abstract 
Alzheimer’s disease (AD) and other age related neurodegenerative diseases share a chronic 
neuroinflammation component in different areas of the brain. The sustained presence of 
neuroinflammation is harmful due to the prolonged release of toxic cytokines by activated 
microglia, which results in damage to the body’s own cells. To model chronic 
neuroinflammation, a cannula delivered lipopolysaccharide (LPS) into the fourth ventricle of 
three month old rats for periods of two, four, and eight weeks. Following two and four weeks 
infusion, the rats showed impaired spatial memory performance on the Morris Water Maze task 
compared to the control group receiving artificial cerebrospinal fluid. However, after eight weeks 
of LPS administration, young rats exhibited a compensatory adaptation, which returned spatial 
memory performance to that of the control group. It was hypothesized that the microglia in the 
young brain had shifted from the classical M1 phase associated with damaging defense to the 
alternative M2a activation associated with repair. The correlation of Morris Water Maze 
performance and immunohistochemical analysis of Major Histocompatability Complex II and 
Peroxisome Proliferator-Activated Receptor gamma expression failed to support this hypothesis. 
Further understanding the underlying less destructive path will provide possible targets for 
intervention in AD, as inducing these adaptations may prevent further damage. 
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Alternate Activation of Microglia as a Protective Adaptation against Chronic Neuroinflammation 
in Young Rats 
In 2006, 26.6 million people world-
wide suffered from Alzheimer’s disease (AD), 
and the prevalence is estimated to quadruple 
by the year 2050, affecting 1 in 85 people 
(Figure 1) (Brookmeyer, Johnson, Ziegler-
Graham, & Arrighi, 2007). AD is a debilitating 
neurodegenerative disorder that primarily 
affects the aged population. The principle 
behavioral symptom which manifests in AD 
patients is memory impairment. Someone with 
AD may get lost in once familiar places, forget biographical information, and become 
disoriented to time and place (Förstl & Kurz, 1999). This behavioral deficit is linked to the 
extensive atrophy of the hippocampal region, which is associated with learning and memory 
(reviewed in Gu, Jiang, & Huang, 2010).  
While the molecular basis of AD pathology remains elusive, researchers have begun to 
uncover its complex networks. Research indicates that both aggregates of beta-amyloid (Aβ) and 
tau proteins initiate a cascade of immune system responses that includes the formation of 
chemokines, cytokines, and membrane attack complexes (Figure 2) (Shen et al., 2001). Though 
hallmark clinical features of inflammation, such as swelling, heat, redness, and pain, do not 
manifest in AD, evidence of neuroinflammation is prominent in the tissue of those affected by 
this neurodegenerative disorder (reviewed in Gasparini, Ongini & Wenk, 2004).  Current AD 
Figure 1. Worldwide Prevalence of Alzheimer’s disease. Using 
data from the United Nations worldwide population forecasts, 
it was projected that with the aging population, the worldwide 
prevalence of AD is expected to rise to 106.2 million by the 
year 2050 (Brookmeyer et al., 2007). 
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research aims to connect the mechanisms of 
neuroinflammation with the etiology and 
treatment of AD.  
A healthy individual has minimal 
baseline inflammation. Following injury or 
pathogenic invasion, the body can mount 
both selective and non-selective immune 
responses. Upon sensing small chemical 
changes in the environment, cells called 
macrophages become activated and travel to the site of damage, where they engulf pathogens 
and debris; microglia are specialized macrophages found in the central nervous system (CNS) 
(reviewed in Kreutzberg, 1995). Inside the macrophage, Major Histocompatibility Complex II 
(MHCII) picks up a piece of partially digested protein and presents it outside the cell to attract a 
specific T cell (Figure 3). For the non-specific response, highly reactive molecules, including 
nitric oxide (NO) and 
reactive oxygen species 
(ROS), are released from the 
macrophage and cause 
indiscriminative damage to 
surrounding material. In 
addition, inflammatory 
mediators called cytokines 
are released, including 
Figure 2. Pathological cycle in Alzheimer’s Disease. The 
neuropathologic features of Alzheimer disease include ß-amyloid 
plaques, neurofibrillary tangles, synapse and neuronal 
dysfunction and loss, reduced neurotransmitter concentrations, 
and activation of glial cells with expression of proinflammatory 
cytokines (Sue & Griffin, 2006). 
Figure 3. The role of MHC II. MHC class II displays partially digested antigens on the 
surface of activated microglia to attract appropriate T cells of the immune system. 
(Parham, 2000) 
Alternate Activation     5 
 
interleukin(IL)-6, tumor necrosis factor (TNF)-α, and IL-1β (reviewed in Miyata & Eeden, 
2011). Acute activation of this immune cascade is beneficial by destroying invaders and cleaning 
up cellular debris. However, chronic activation of this cascade inflicts considerable damage to 
cells that the body relies on for proper functioning of memory, affect, and cognition. It is thought 
that the “balance” of these pro- and anti-inflammatory signals may determine the susceptibility 
and outcome of disease (reviewed in Rubio-Perez & Morillas-Ruiz, 2011). 
The typical aged brain contains an overall increased level of inflammation, which proves 
to have damaging effects on learning and memory. An increase in the pro-inflammatory cytokine 
IL-1β leads to decreased neurogenesis, an essential component to hippocampal function and 
memory formation (Kuzumaki et al., 2010). This age-related increase of IL-1β is accompanied 
by a decrease in the anti-inflammatory IL-4 cytokine in the hippocampus of aged rats with poor 
Long Term Potentiation (LTP) (Maher, Nolan, & Lynch, 2005). In a transgenic mouse model of 
AD, increased production of the proinflammatory cytokine IL-6 leads to inflammatory 
neurodegeneration and impairs memory task performance, including avoidance learning (Heyser, 
1997). IL-6 also compromises hippocampal neurogenesis (Vallieres, Campbell, Gage, & 
Sawchenko, 2002). Restoring the balance of pro-inflammatory and anti-inflammatory factors 
could potentially prevent further hippocampal damage and return memory function towards 
baseline (Figure 4). 
Figure 4. Spectrum of Cytokines Regulating Inflammation. Cytokines are chemicals that regulate the level of inflammation. 
While each cytokine generally has its own broad spectrum of actions, some are thought it be more potent in their actions than 
others. (reviewed in Petermann & Korn, 2011). There exists a general trend from extremely pro-inflammatory to extremely 
anti-inflammatory. The balance among them determines the overall amount of inflammation. 
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In the rodent model of chronic neuroinflammation, chronic administration of 
lipopolysaccharide (LPS) into the fourth ventricle reproduces many of the behavioral, 
neurochemical, and neuropathological changes associated with AD (Hauss-Wegryzyniak, 
Dobrzanski, Stoehr, & Wenk, 1998). It provokes extensive inflammatory responses in the 
hippocampus and its subregions, including the increase of IL-1β and TNFα (Hauss-Wegryzyniak 
et al., 1998). Microglia from aged brains have a more intense reaction to LPS than microglia in 
younger brains; this results primarily in greater increases in glial expression of IL-6 and IL-1 
(Xie, Morgan, Rozovsky, & Finch, 2003). Studies with transgenic mice lacking the IL-6
 
gene 
demonstrate that without IL-6, high circulating levels of TNFα and IL-1β are not sufficient to 
disrupt working memory (Sparkman et al., 2006). This suggests that the increased IL-6 in aged 
brains may exacerbate the cognitive decline associated with inflammation. 
In addition to the 
damaging, defensive role, 
microglia can also specialize in 
the resolution of inflammation and 
the repair process (Figure 5) 
(Mills, Kincaid, Alt, Heilman, & 
Hill, 2000). The “classical” (M1) 
macrophage is associated with the 
oxidative damage seen in AD and 
releases the pro-inflammatory 
cytokines TNFα, IL-1, and IL-6 
(Khoury et al., 2007). Increased 
Figure 5. Markers for macrophage phenotypes. There are multiple phenotypes 
of activated microglia. Increased MHC II is a marker common to both M1 and 
M2a activation. The present experiment aims to use PPARγ as a marker unique 
to M2a (Cameron & Landreth, 2010). 
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MHCII has been used as a marker for M1 activation. Negative feedback mechanisms trigger the 
reduction of the classical pro-inflammatory response (reviewed in Colton, 2009). The transition 
that decreases the inflammatory response and supports tissue repair includes the release of a 
number of anti-inflammatory cytokines, including IL-4 and IL-13 (reviewed in Colton, 2009).  In 
the presence of IL-4 and IL-13, macrophages may transition into a true anti-inflammatory state 
of activation (Stein, Keshav, Harris, & Gordon, 1992). This repair state of macrophages has been 
coined “alternative activation” (M2a) and is characterized by the release of anti-inflammatory 
cytokines IL-10 and IL-1RA (IL-1 receptor antagonist) (Rutschman et al., 2001). Further, M2a 
uses the enzyme arginase to convert the amino acid L-arginine into urea and ornithine, instead of 
the destructive NO (Rutschman et al., 2001). MHCII is also displayed in alternative activation, 
but unique markers include PPARγ, YM1, YM2, and FIZZ1 (reviewed in Cameron & Landreth, 
2010). It remains to be determined if and when this phenotypic switch is induced in the presence 
of chronic neuroinflammation. 
Using a transgenic mouse model of AD, Jimenez et al. (2008) observed an age-dependent 
switch in microglial activation between M1 and M2a. The expression of inflammatory markers 
TNFα and iNOS were only slightly altered in 6-month-old mice compared to wild type mice. In 
12-month-old transgenic mice, there was a moderate increase in TNFα expression. By the age of 
18 months, the expression of both TNFα and iNOS had significantly increased in the 
hippocampus of the transgenic mice. This suggests a harmful switch from the alternative to the 
classic microglial activation is restricted to old ages and may account for the cognitive decline 
seen in AD (Jimenez et al., 2008). 
To reproduce the chronic inflammatory component of AD and study its consequences, 
the LPS model is used. Previous work has shown that young (3 m.o.) animals which undergo 
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LPS infusion over periods of 
two and four weeks mimic the 
increased neuroinflammation 
and poor spatial memory 
performance in the Morris 
Water Maze (MWM) seen in 
untreated aged (23 m.o.) 
animals (Brothers, Marchalant, 
& Wenk, 2010; Marchalant, 
Cerbai, Brothers, & Wenk, 
2008). A prior experiment by 
Brothers (2010) induced 
chronic neuroinflammation in 
young rats (3 m.o.) via LPS, 
and it was expected that the 
performance on the MWM would be inversely proportional to the amount of MHCII staining; 
increased damage from more activated microglia would lead to poorer performance. Instead, the 
results showed that this relationship only holds true through the first four weeks. By the eighth 
week, it appears that a compensatory mechanism arises to improve spatial memory performance 
in young rats, while MHCII expression levels continue to rise (Figure 6) (Brothers, unpublished 
data). 
The present study aims to determine if a change in microglial activation is the phenotypic 
switch seen in young brains. The hypothesis states that following chronic neuroinflammation, 
Figure 6 (Above) Morris Water Maze Results: Through the first four weeks, LPS 
infusion leads to a decrease in MWM performance. By the 8th week, a 
compensatory mechanism arises to improve spatial memory  in young rats. 
 
(Below). Major Histocompatability Complex II Immunohistochemistry 
Densitometry. MHCII is a marker for activated microglia. As duration of LPS 
infusion increases, the number of activated microglia increases (Brothers, 
unpublished data). 
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microglial activation changes 
from the M1 “classical 
activation” to the M2a “alternate 
activation” state to minimize 
neuronal damage. Therefore, 
while the increased MHCII 
shared by both states continues 
to increase throughout the eight 
weeks post surgery, the PPARγ 
that is characteristic of the alternate state is expected to increase between weeks four and eight 
(Figure 7). If these adaptive mechanisms of young brains are better understood, they may be able 
to be induced in aged brains to protect against the ill effects of chronic neuroinflammation.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Predicted Results. The prediction states over time the relative density of 
PPARγ will increase and the latency to reach the platform will decrease. 
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Methods 
As previously described (Hauss-Wegrzyniak et al., 1998), sixty young male Fischer rats 
underwent surgical implantation of an osmotic mini-pump which delivered a chronic infusion of 
lipopolysaccharide (LPS) or artificial cerebral spinal fluid (aCSF) via a cannula into the IVth 
ventricle; two, four, or eight weeks later, the animals underwent behavioral testing with the 
Morris Water Maze. Following sacrifice, immunohistochemistry was utilized to examine PPARg 
protein expression. 
Subjects and Surgery 
Sixty young (4 m.o.) male Fischer rats (Harlan Sprague–Dawley, Indianapolis, IN) were 
individually housed in Plexiglas cages with free access to food and water. The rats were 
maintained on a 12-h light/dark cycle in a temperature-controlled room (22˚C) with lights off at 
09:00. Health of the rats was assessed upon arrival and throughout the experiment. During the 
first week, they were familiarized with their new environment and handled by the investigators 
prior to surgery.  
Cannula Implantation 
Each rat was anesthetized with isoflurane and securely placed into a stereotaxic 
apparatus. After making an incision, a hole was drilled down to dura (at approximately -2.5AP, 
0.0LM). A cannula was inserted into the fourth ventricle and secured with acrylic. A 
subcutaneous osmotic minipump (Alzet model #2006, to deliver 0.15µl/hr; Durect Corp., 
Cupertino, CA, USA) and tubing (Tygon tubing, 0.06 O.D.) were implanted to deliver the 
reservoir of fluid to the cannula. This allowed aCSF (140 mM NaCl, 3.0 mM KCl, 2.5 mM 
CaCl2, 1.0 mM MgCl2, and 1.2 mM Na2HPO4 adjusted to pH 7.4) or LPS (0.25µg/hr, 1.66 
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mg/ml dissolved into aCSF;  Sigma, St. Louis, MO, USA E. coli, serotype 055:B5, TCA 
extraction)  to be chronically infused for a period of up to eight weeks. Animals were sutured, 
given lidocane, and fed a high caloric diet until they appeared to be gaining weight normally. 
Behavioral Testing 
The Morris Water Maze (MWM) was used to assess spatial learning ability. The animals 
were tested two, four, or eight weeks following surgery. A clear, circular platform (10 cm in 
diameter) was submerged 2.5 cm underwater inside a 185 cm diameter pool and kept in a 
constant location. The testing site had white walls with proximal and distal visual clues. The rats 
were tracked by an overhead video camera connected to a tracking unit (Nagedus EthoVision 
3.1, Nagedus, Leesburg, VA), which recorded latency to find the platform, distance traveled, 
speed, and other variables.  
On the first day, rats were placed upon the hidden escape platform for 30s. Subsequently, 
they completed three sets of two consecutive trials (6 trials/day) with 1 hour between sets, and 
repeated this over the next three days (24 trials total). During each trial, the animal was randomly 
placed into the pool from one of six entry points that were evenly spaced along the edge of the 
pool. The trial ended after the rat found the hidden platform or 60s had elapsed.  The animal 
remained or was placed on the platform for an additional 30s following each trial.  Latency to 
find the platform across days was analyzed. Measures of general movement such as swim speed 
and thigmotaxis were also analyzed for possible motor impairments.  On the fifth day, four 
regular trials were run and recorded. One probe trial (without platform) was performed to ensure 
that the rat cannot see the submerged platform; good test performance showed the rat spending 
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the most time in the quadrant that formerly housed the platform. Two visible platform trials (2 
cm above water) were performed to ensure the rat was free of visual deficits. 
Histological Procedures 
Fixation 
Following the behavioral testing, each rat was anesthetized with isoflurane and 
underwent a transcardiac perfusion (10ml/min) with saline (0.9%, 80mL) containing heparin (1 
U/mL), followed by 4% paraformaldehyde in 0.1 M phosphate buffered saline (PBS; pH 7.4, 120 
mL). Brains were removed and stored in the 4% paraformaldehyde fixative solution at 4˚C, then 
transferred to PBS. The brains were sliced into 40μm coronal sections via vibratome (Leica) and 
stored in an antifreeze solution (0.5 M phosphate buffer with glycol ethylene and glycerol) until 
staining. 
Immunohistochemistry 
Slices containing the hippocampus and the cingulate cortex were selected for 
immunohistochemistry to visualize the transcription factor PPARgamma. Unless otherwise 
noted, all steps were performed on an agitator at 22˚C; all rinses were performed with PBS (1M 
3x10min). The tissues were rinsed to clear antifreeze, then mounted onto slides and outlined with 
a hydrophobic pen (Liquid Blocker).  
Antigen Retrieval 
The slides were put into boiling 0.1 M citric acid (pH 6.0; microwave 2 min, power 10) 
and microwaved (5 min, power 2), then allowed to cool at rt. A trypsin digest (abcam, #ab970) 
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was performed for 15 min and rinsed. This aimed to enhance the signal of immunohistological 
staining.  
Peroxidase Reaction Staining 
A quench was performed with 0.3% H2O2, 10 M PBS, and quenching stock for 60 min to 
block endogenous peroxidase activity and rinsed. Blocking was performed in NGS (5%) to 
prevent non-specific staining. The tissues were incubated in a PPARγ primary antibody (1:100 
dilution, rabbit polyclonal, Santa Cruz, #SC-7196) at 4˚C overnight. The following day, the 
tissue was rinsed then bathed in the biotinylated goat-antirabbit 2˚ antibody (1:200 dilution, 
120min, Vector, Burlingame, CA, #BA-1000) for 120 min. After rinsing, the tissue was treated 
with an avidin-biotinylated horseradish peroxidase Elite Kit (Vectastain, Elite ABC kit, Vector), 
then rinsed again. The tissue was stained using 3,3’-diaminobenzidine tetrahydrochloride as 
chromogen (2.5mL PBS, 125μL 1% H2O2, 125μL 1% DAB, Vector, Burlingame, CA) until 
desired color was reached (5 min), and the reaction was stopped by rinsing with buffer. The 
tissue was rinsed in 1M PBS and 95% ethyl alcohol. The slides were dehydrated (2 min each of 
75% EtOH, 90% EtOH, 100% EtOH, 100%EtOH, xylene, xylene) and coverslipped with 
cytoseal mounting medium. 
Histological Analysis 
The tissues were examined using brightfield light microscopy (Nikon 90i microscope and 
NIS Elements software). Histochemical examination of the hippocampus was performed using 
two representative slides per animal. 
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Results and Discussion 
Observations from immunohistochemistry fail to support the hypothesis that young brains 
transition to a less destructive form of microglial activation under conditions of chronic 
neuroinflammation. There were no distinctive differences in the patterns of PPARγ staining 
acquired by the tissue between experimental groups over time (Figure 8). Previous OX-6 staining 
in our lab has demonstrated that the young animals increase the amount of MHC-II synthesized 
as the duration of LPS infusion increases (Brothers, unpublished data). This MHC-II can be a 
marker for either M1 activation or M2a activation (reviewed in Cameron & Landreth, 2010). The 
transcription factor PPARγ was chosen as a marker because high expression levels of it are a 
Figure 8. PPARγ Immunohistochemistry. There were no distinctive differences in the patterns of PPARγ staining acquired by 
the tissue between experimental groups over time, including LPS 4 weeks (10x, sc 1:100, upper left; 20x, sc 1:100 bottom left) 
and LPS 8 weeks (10x, sc 1:100, upper right; 20x, sc 1:100, bottom right. However, a considerable amount of non-specific 
background staining was present. 
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characteristic of M2a microglial activation, but not M1 activation (reviewed in Cameron & 
Landreth, 2010). The coloration in the PPARγ stain was diffuse throughout the brain and 
appeared to be primarily localized to intercellular space, but the PPARγ transcription factor 
should be localized to the nucleus. A review by Bordeaux et al. examines the high frequency of 
non-specific antibodies on the market and increases confidence in this claim of poor antigenic 
accuracy (2010). Without a reliably measured comparison in PPARγ between groups, no 
conclusion can be drawn about the activation state of the microglia. There may be no change in 
activation state or current PPARγ antibodies may be inadequate. 
After following the protocol from two different manufacturers (abcam, ab-19481; santa 
cruz; sc-7196), the resulting stains did not resemble the sample photos they provided (Figure 9). 
Much of the color acquired 
by the tissue was thought to 
be non-specific background 
staining. Various measures 
were taken to increase the 
permeability of the membranes 
to reach the intranuclear PPARγ protein and enhance the signal of the immunohistological stain. 
Tween or TritonX-100 was added to the phosphate buffered saline solution to act as a detergent. 
Heat Induced Epitope Retrieval was performed using Tris-EDTA and citrate buffers in 
waterbaths and microwaves of varying durations and temperatures. Proteolytic Induced Antigen 
Retrieval was performed with a trypsin digest. Individual and combinations of these 
pretreatments only provided minor improvements, if any. Because PPARγ is known to be an 
intranuclear protein, one measure of the specificity of the antibody would examine its 
Figure 9. Abcam and Santa Cruz sample PPARγ IHC images. The above images 
were representative IHC stains shown from two primary antibody vendors, 
Abcam (left) and Santa Cruz (right). 
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localization. Eosin B, a cytoplasmic stain, was used in combination with PPARγ and no clear 
localization of the PPARγ protein was found. The poor results of the immunohistochemical stain, 
despite many protocols borrowed from other successful PPARγ researchers, suggests that current 
PPARγ antibodies are ineffective for the examination of brain tissue. 
 Despite the lack of success with current polyclonal antibodies, the possibility of 
microglial activation mediating a repair state remains an important mechanism to be examined. If 
clear results cannot be reached using PPARγ immunohistochemistry, then other avenues must be 
explored. One possible direction is to measure other markers that are also unique to the M2a 
state, such as the levels of expression of FIZZ1, YM1, YM2, and mannose receptors (reviewed 
in Cameron & Landreth, 2010); perhaps these other markers have more effective antibodies 
available. Another way to approach the research question would be to directly monitor the 
cytokine profile expressed following chronic neuroinflammation.  A predominant presence of 
TNFα, IL-1β, and IL-6 would suggest the M1 activation, whereas a change to IL-10 and IL-1Ra 
would suggest the M2a 
activation (Khoury et al., 
2007; Rutschman et al., 
2001). Many avenues are 
available to continue the study 
of the microglial response to 
chronic neuroinflammation 
(Figure 10). 
Figure 10. Macrophage Functional Phenotypes. Each state of microglial activation has 
characteristic activating signals, secretory products, and biological markers. 
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It is important to continue to extract information from the LPS paradigm in order to 
examine the immune response of the brain following the periods of chronic neuroinflammation 
experienced with many neurodegenerative diseases affecting the aged. Following mild brain 
injury, the young human brain exhibits greater long-term cognitive functioning compared to the 
aged brain (Senathi-Raja, D., Ponsford, J., & Schönberger, M., 2010). This pattern is effectively 
mirrored by our LPS paradigm. By the eighth week of a chronic immune response, the spatial 
memory of the young experimental LPS group recovers to that of the young control group 
(Brothers, unpublished data). However, old (24 mo) rats do not show this return to baseline 
(Marchalant et al., 2008). Further understanding the underlying less destructive response 
exhibited by young brains will provide possible targets for intervention in AD, as inducing these 
adaptations may prevent further damage. 
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